| Name | Heritage Center |
|---|---|
| Location | 101-13th Street, Huntington, West Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 160 |
| Occupancy Rate | 83.38% |
| Medicare ID (CCN) | 515060 |
| Legal Business Name | 101 13th Street Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1619924842 |
| Organization Name | HRWV OF HUNTINGTON, INC. |
| Doing Business As | HERITAGE CENTER |
| Address | 101 13th St, Huntington, WV 25701 |
| Phone Number | 304-525-7622 |
News Archive
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.
› Verified 2 days ago
| NPI Number | 1912181223 |
| Organization Name | 101 13TH STREET OPERATIONS LLC |
| Doing Business As | HERITAGE CENTER |
| Address | 101 13th St, Huntington, WV 25701 |
| Phone Number | 304-525-7622 |
News Archive
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $130166 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 26.09 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.87 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 20.9 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.7 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.22 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.89 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 86.02 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.41 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 49.26 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.23 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 38.22 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28.23 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.77 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.37 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 60.64 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 53.68 | 82.93 |
News Archive
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.
› Verified 2 days ago
Huntington Health And Rehabilitation Center Location: 1720 17th Street, Huntington, West Virginia 25701 Phone: (304) 529-6031 | |
Madison Park Healthcare Location: 700 Madison Avenue, Huntington, West Virginia 25704 Phone: (304) 522-0032 | |
St. Mary's Hospital Location: 2900 First Street, Huntington, West Virginia 25702 Phone: (304) 526-8983 |